Clinical evaluations of β₂-microglobulin adsorbing Lixelle columns; S-15 and S-35 A multi-center study

Abstract

We applied β₂-microglobulin adsorbing Lixelle column of different sizes (Lixelle S-15: 65mL of priming volume, S-35: 177mL of priming volume) to patients (S-15: 28 males and 38 females; S-35: 29 males and 24 females) with dialysis-related amyloidosis (DRA), and compared the incidence of adverse effects, the degree of improvement in clinical symptoms such as joint pain, and β₂-microglobulin adsorbing efficiency between Lixelle S-15 and S-35 columns. The incidence of adverse effects such as hypovolemia or decrease in hematocrit was reduced in Lixelle S-15 (8%) compared to that (25%) in Lixelle S-35. Lixelle S-15 exhibited about 90% (vs S-35) efficiency in adsorption of β₂-microglobulin combined with high-performance membrane dialyzer and the same efficacy as with S-35 in improvement of clinical symptoms. Change from S-15 to S-35 was necessary for some patients due to worsening shoulder pain. Lixelle S-15 was considered useful for patients with DRA to whom Lixelle S-35 is not applicable because of adverse effects.